Individualized prehabilitation between neoadjuvant treatment and surgery in high-risk patients with gastrointestinal tumor - a pilot study
Not Applicable
Recruiting
- Conditions
- C15C16C20Malignant neoplasm of oesophagusMalignant neoplasm of stomachMalignant neoplasm of rectum
- Registration Number
- DRKS00018816
- Lead Sponsor
- Klinikum St. Georg GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
min. 70 years old
patients with oesophageal-, gastral or rectal cancer
min. ASA-score of 3
Exclusion Criteria
dementia
bed confinement
emergency surgery indicated
enteral nutrition not possible
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method complication rate in Clavien-Dindo
- Secondary Outcome Measures
Name Time Method hospital length of stay, mortality, compliance
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by prehabilitation in gastrointestinal cancer patients undergoing neoadjuvant therapy?
How does individualized prehabilitation compare to standard preoperative care in reducing post-surgical complications for high-risk gastrointestinal tumor patients?
Which biomarkers correlate with improved postoperative outcomes in high-risk gastrointestinal cancer patients receiving prehabilitation?
What adverse events are associated with prehabilitation protocols in patients with malignant neoplasms of the oesophagus, stomach, or rectum?
Are there combination therapies or pharmacological agents that enhance prehabilitation efficacy in gastrointestinal cancer patients with neoadjuvant treatment?